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1110-78 Ventricular Arrhythmias Following Autologous Skeletal 
Myoblast Implantation 
Warren Sherman, Kun-Lun He, Geng-Hua Yi, Hua Zhou. Angou Gu, Eva M. Becker, Ge- 
Ping Zhang, Jack Harvey, Race Kao. Myung J. Lee, Jle Wang, Howard Haimes, Daniel 
Burkhoff, Mount Sinai School of Medicine, New York, NY, Columbia University School of 
Medicine, New York, NY 
Background: Cellular cardiomyoplasty using autologous skeletal myoblasts (ASM) has 
been proposed as treatment for congestive heart failure (CHF). Early clinical use of this 
technique has raised concerns regarding the incidence of ventricular tachyarrhythmias 
and sudden death. We performed ambulatory monitoring in dogs with CHF after receiv- 
ing ASM injections. 
Methods: 15 dogs underwent induction of CHF by coronary microembolization. After 4 
weeks, injections of ASM (280.780 million ceils) or saline were delivered by either open- 
chested epicardial (EPI) or transcatheter endoventricular (ENDO) methods. Multiple 24 
hour ambulatory ECGs (AECG) were recorded at baseline (preinjection) and at weeks 4. 
8 and 10 after injection. AECGs were reviewed for VT Unexpected terminal events were 
tabulated. 
Resul1s: Four groups of dogs were identified: ASM/EPI (5), ASM/ENDO (4), saline/EPl 
(3), and saline/END0 (3). 73 interpretable AECG were evaluated. Occurrences of ven- 
tricular tachycardia (VT) or death (Dj are as belpw. The majority of events were obsewed 
in 6 of 15 dogs. There was no relationship between VT and #cells injected or #injections 
par dog. 
Conclusion: In this model of myocardial dysfunction and cellular cardiomyoplasty. the 
injection of ASM did not result in an increase in death or ventricular tachycardia during 
the monitored periods. 
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1110-79 Contractile Response and Mitral Regurgitation After 
Late Withdrawal of Biventricular Pacing 
Roland R. Brana Christian Reiner, Johannes Sperzel. Heinz F. Pitschner. Christian W 
Hamm, Kerckhoff Heart Center, Bad Nauhelm, Germany 
Background: Biventricular pacing @VP) is a promising treatment modality for patients 
with symptomatic heart failure (HF) and mechanical dyssynchrony in the setting of left 
bundle branch block or intraventricular conduction delay. Clinical studies have shown 
short-term improvement in contractile function and long-term improvement in clinical sta- 
tus in association with reverse left ventricular (LV) remodeling. The aim of this study was 
to investigate the hemodynamic consequences of late biventricular pacing (BVP) with- 
drawal. 
Methods: Eleven patients (6459 years) received a BVP system because of severe HF 
(NYHA class Ill) due to idiopathic (1x6) or ischemic (n=3) LV dysfunction and a QRS 
interval >150 msec. Patients were studied 459+259 days after continuous BVP. Thereaf- 
ter, the BVP mode was deactivated (Off) and patients were restudied after an equilibra- 
tion period of 72 hours on constant medication. The rate of LV pressure rise (dPldt) was 
estimated by measuring the time intewal between 1 and 3 mlsec on the mitral regurgita- 
tion (MR) continuous-wave Doppler spectrum. MR severity was assessed with the color 
Doppler jet area and effective regurgitant orifice area (ERO) derived from the PISA 
method. 
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Conclusion: Late withdrawal of biventricular pacmg leads to a de&e m LV systolic per- 
formance and an increase in functional MR despite a lower blood pressure. These results 
indicate a sustained long-term hemodynamic benefit of biventricular pacing independent 
of a rswrse LV remodeling process. 
1110-80 Impact of Cardiac Resynchronization on Mortality From 
Progressive Heart Failure 
DavidJ. Bradley, Elizabeth A. Bradley, Kenneth Lee Baughman, Ronald D. Berger, Hugh 
Calkins, Steven N. Goodman. David A. Kass. Neil R. Powe, Johns Hopkins Medical 
Institutions, Baltimore, MD 
Background: Cardiac resynchronization improves cardiac function, exercise capacity, 
and quality of life among heart failure patients. The effect of cardiac resynchronization on 
mortality from progressive heart failure, however, is uncerlain. To determme whether car- 
diac resynchronization decreases mortality from progressive hearl failure, we conducted 
a meta-analysis of randomized trials. 
Methods: Medline, Embase, and the Cochrane Controlled Trials Register were searched 
for reports of randomiied controlled trials of cardiac resynchronization for the treatment 
of chronic symptomatic left ventricular dysfunction among patients with prolonged QRS 
intervals. Eligible studies had at least three months of follow-up. Reports of crossover tri- 
als were excluded if the first randomized crossover phase was less than three months. 
Trials were rewewed independently by two investigators. Trial data were pooled using a 
random effects statistical model. 
Results: Outcomes from trials with 1634 total patients were included in the meta-analy- 
sis. Baseline patient characteristics were similar in the included trials, and the majority of 
patients were men with moderate to severe heart failure symptoms at baseline (New 
York Heart Association functional class Ill and IV) and prolonged QRS intervals. Pooled 
data showed that progressive heart failure mortality was 1.7% for cardiac resynchroniza- 
tion patients and 3.5% for controls over three to six months of follow-up. Cardiac resyn- 
chronization reduced death from progressive heart failure by 51% relative to controls (p = 
0.029). There was not evidence of quantitative heterogeneity by a chi-square test 
(p=O.85), suggesting a consistent effect across trials. 
Conclusions: Cardiac resynchronization appears to reduce mortality from progressive 
heart failure over three to six months of follow-up in patients with symptomatic left ven- 
tricular dysfunction and prolonged ORS intervals. This finding suggests that cardiac 
resynchronization may have a positive Impact on the most common mechanism of death 
among patients with advanced heart failure. 
11 IO-81 Acute Hemodynamic Effects of Pacing Therapy on Left 
Ventricular Function in Patients With Heart Failure and 
Atrial Fibrillation: Comparison of Left Ventricular 
Pacing and Biventricular Pacing 
Taro Okada, Yukihiko Yoshida. Makoto Kondo, Kosuke Watanabe, Masahiro Mutoh, 
Takumi Yamada. Tomomitsu Tani, Shoji Yamakami, Kazuki Iwata, Yoshimasa 
Murakami, Toyoaki Matsushita, Mitsuhlro Okamoto. Naoya Tsuboi, Haruo Hirayama, 
Teruo Itoh, Junji Toyama. Owari Hospital. IchinomiyaGity, Japan, Nagoya Daini Red- 
Cross Hospital, Nagoya-City. Japan 
Background: It has been reported that both biventricular pacing (BVP) and left ventricu- 
lar pacing (LVP) similarly improve lefi Ventricular (LV) function in patients with heart fail- 
ure and sinus rhythm (S). However it is not clear which pacing mode may be preferable 
in patients with heati failure and atrial fibrillation (AF). 
Methods: Hemodynamic parameters were studied in 18 patients (Mean&EM: QRS 
duration 178iQms. LVEF 25.7*1.6%). Patients were stimulated in either the VVI mode (7 
patients with AF) or the DDD mode (11 patients with S) at a rate of QObpm. Ventricular 
pacing was given in the right ventricular apex, LV lateral free wall via coronary sinus, and 
both ventricles simultaneously. In patients with AF, data under baseline rhythm were 
compared with pacing at varying ventricular sites. In patients with S, atrioventricular inter- 
val was decreased by 20ms decrements from 200 to 60 ms for 3 minutes each and opti- 
mal atrioventricular interval with the largest dpidtmax was determined at varying pacing 
sites. Data under AAI pacing at 90 bpm were compared with DDD pacing at varying ven- 
tricular sites with each optimal atrioventricular interval. 
Results: In patients with AF, right ventricular pacing (RVP) had negligible contractile 
effects. However, LVP and BVP raised dp/dtmax by 25.5*3.1% and 21.4+4.3%, respec- 
tively (P<O.Ol and P<O.Ol, versus RVP 4.1*3.5%).The data was similar in patents with S 
(LVP 34.9+4.5%, BVP 31.0+4.6%, RVP -1.2+3.2%). With regard to LV diastolic funCtiOn, 
there was no improvement during RVP and LVP, however significant improvement was 
observed during BVP in patients with AF. BVP Improved dpldtmin by 19.1*1.3% 
(P<O.OOl versus RVP 6.1*3.2% and LVP 2.6+1.2%), and pressure half time by 
20.1&.9% (P<O.Ol versus RVP 5.7*2.7% and LVP -1.2+1.9%). In patients with S, DDD 
